Non-alcoholic fatty liver disease as a risk factor for anemia of chronic inflammation (experimental research)

The aim of the study. In recent years, non-alcoholic fatty liver disease (NAFLD) has been considered a hepatic manifestation of the metabolic syndrome. The main consequence of NAFLD is chronic hepatic inflammation, which leads to dyslipidemia, inflammation, increased oxidative stress, and endothelial dysfunction. Immune activation in response to interaction with agents of a metabolic nature induces the release of pro-inflammatory cytokines in the liver, which subsequently cause iron сhomeostasis disorder. This leads to a frequent association of NAFLD with anemia of various etiology. In this regard, we considered it important to assess the severity of the systemic inflammatory response in NAFLD in the experiment in order to -diagnose anemia of chronic inflammation.

Materials and methods. The study was carried out on 26 male Wistar rats, which were divided into control and experimental groups. In animals of the experimental group, NAFLD was modeled according to the generally accepted method. In order to assess metabolic disorders, we determined the main biochemical parameters, a complete blood count with the calculation of erythrocyte indices, the concentration of the main pro-inflammatory cytokines – interleukin (IL) 1, IL-6.

Results. In laboratory rats with NAFLD, a statistically significant increase of intrahepatic enzymes in blood serum was found. The state of the erythrocyte lineage of hematopoiesis in the experimental group progressively worsened and caused the development of anemic syndrome. Synchronously, a statistically significant increase in serum levels of IL-1, IL-6 was recorded, which confirms the correlation of NAFLD with anemia of chronic inflammation.

Conclusions. A high concentration of IL-1, IL-6 cytokines in NAFLD inhibits iron absorption in the duodenum, leads to the activation of macrophages, blocking the release of iron processed from aging erythrocytes into plasma. Further study of the mechanisms of anemia in NAFLD provides important therapeutic targets in the treatment of both NAFLD and its comorbidities.

1. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2): 197-211. doi: 10.1080/03602532.2017.1293683

2. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019; 133(1): 40-50. doi: 10.1182/blood-2018-06-856500

3. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008; 111(4): 2392-2399. doi: 10.1182/blood-2007-05-090019

4. González-Domínguez Á, Visiedo-García FM, DomínguezRiscart J, González-Domínguez R, Mateos RM, Lechuga-Sancho AM. Iron metabolism in obesity and metabolic syndrome. Int J Mol Sci. 2020; 21(15): 5529. doi: 10.3390/ijms21155529

5. Stein J, Connor S, Virgin G, Ong DE, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016; 22(35): 7908-7925. doi: 10.3748/wjg.v22.i35.7908

6. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron

7. deficiency anemia: diagnostic and therapeutic implications. Blood. 2009; 113(21): 5277-5286. doi: 10.1182/blood-2008-12-195651

8. Brus TV, Pyurveev SS, Vasil’eva AV, Zabezhinskiy MM, Kravtsova AA, Pakhomova MA, et al. Morphological liver changes in case of various ethiology fatty distrophy. Russian Biomedical Research. 2021; 6(3): 21-26. (In Russ.).

9. Brus TV, Pyurveev SS, Kravtsova AA, Balashov LD. Comparative characteristics of models of fatty degeneration of the liver of various origins. Children’s Medicine of North-West. 2021; 9(1): 66-67. (In Russ.).

10. Brus TV, Vasiliev AG, Trashkov AP. The main biochemical markers of non-alcoholic fatty liver disease of various severity (experimental study). Pathological Physiology and Experimental Therapy, Russian Journal. 2022; 66(1): 44-51. (In Russ.). doi: 10.25557/0031-2991.2022.01.44-51

11. Dicheva DT, Andreev DN, Partsvania-Vinogradova EV, Umyarova RM. Steatohepatitises: Etiological variants, principles of diagnosis and management. Medical Council. 2022; 16(6): 74-82. (In Russ.). doi: 10.21518/2079-701X-2022-16-6-74-82

12. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, et al. Fructose-induced fatty liver disease hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005; 45: 1012-1018. doi: 10.1161/01.HYP.0000164570.20420.67

13. McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int. 2006; 26: 389-398. doi: 10.1111/j.1478-3231.2006.01228.x

14. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002; 22(1): 83-96. doi: 10.1055/s-2002-23205

15. Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: Hepatitis-associated aplastic anaemia – A syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009; 30(5): 436-443. doi: 10.1111/j.1365-2036.2009.04060.x

16. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004; 71(Suppl 3): S17-S21. doi: 10.3949/ccjm.71.suppl_3.s17

17. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology. 2006; 44: 1039-1046. doi: 10.1002/hep.21303

18. Kuzmina YuB. Non-alcoholic fatty liver disease and associated pathology of the cardiovascular system: Clinical and ultrasound picture. Modern Science: Actual Problems of Theory and Practice. Series “Natural & Technical Sciences”. 2022; 1: 177-181. (In Russ.). doi: 10.37882/2223-2966.2022.01.19

19. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704): 2090-2093. doi: 10.1126/science.1104742

20. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18): 3313-3327. doi: 10.1007/s00018-018-2860-6

21. Lee YG, Chang Y, Kang J, Koo DH, Lee SS, Ryu S, et al. Risk factors for incident anemia of chronic diseases: A cohort study. PLoS One. 2019; 14(5): e0216062. doi: 10.1371/journal.pone.0216062

22. Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: Results of a large, prospective, observational study. Haematologica. 2015; 100(1): 124-132. doi: 10.3324/haematol.2014.112813

23. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol. 2009; 15(37): 4653-4658. doi: 10.3748/wjg.15.4653